Francesca Cardarelli, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 17 | 2021 | 4251 | 1.790 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2019 | 66 | 0.820 |
Why?
|
| Polyomavirus Infections | 2 | 2020 | 197 | 0.790 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 452 | 0.750 |
Why?
|
| Delayed Graft Function | 1 | 2019 | 48 | 0.700 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2019 | 277 | 0.640 |
Why?
|
| Thigh | 1 | 2019 | 247 | 0.630 |
Why?
|
| HLA-DQ Antigens | 1 | 2018 | 210 | 0.620 |
Why?
|
| Graft Rejection | 8 | 2020 | 4397 | 0.600 |
Why?
|
| Histocompatibility Testing | 1 | 2018 | 741 | 0.550 |
Why?
|
| BK Virus | 3 | 2020 | 129 | 0.470 |
Why?
|
| Renal Dialysis | 4 | 2019 | 1786 | 0.460 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2009 | 1873 | 0.380 |
Why?
|
| Kidney Failure, Chronic | 5 | 2018 | 2538 | 0.340 |
Why?
|
| HLA Antigens | 2 | 2005 | 1381 | 0.340 |
Why?
|
| Isoantibodies | 2 | 2006 | 679 | 0.250 |
Why?
|
| Multiple Myeloma | 2 | 2021 | 5181 | 0.240 |
Why?
|
| Creatinine | 2 | 2009 | 1919 | 0.240 |
Why?
|
| Graft Survival | 5 | 2018 | 3737 | 0.210 |
Why?
|
| Postoperative Complications | 3 | 2020 | 15295 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 3523 | 0.190 |
Why?
|
| Interferon-alpha | 1 | 2004 | 895 | 0.180 |
Why?
|
| Venous Pressure | 1 | 2019 | 56 | 0.180 |
Why?
|
| Phosphorus | 3 | 2011 | 338 | 0.170 |
Why?
|
| Ligation | 1 | 2019 | 453 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 5 | 2018 | 2170 | 0.160 |
Why?
|
| Cold Ischemia | 1 | 2018 | 65 | 0.160 |
Why?
|
| HLA-DR Antigens | 1 | 2018 | 645 | 0.140 |
Why?
|
| Antibodies | 1 | 2004 | 2460 | 0.140 |
Why?
|
| Virus Activation | 1 | 2017 | 319 | 0.130 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 732 | 0.120 |
Why?
|
| Dexamethasone | 1 | 2021 | 1951 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2004 | 2119 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2017 | 599 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 820 | 0.100 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 332 | 0.090 |
Why?
|
| Male | 20 | 2021 | 350118 | 0.090 |
Why?
|
| Middle Aged | 16 | 2021 | 213383 | 0.090 |
Why?
|
| Antiviral Agents | 2 | 2018 | 2987 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2019 | 2925 | 0.080 |
Why?
|
| Manometry | 1 | 2011 | 445 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 1855 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 9274 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2020 | 7729 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 638 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 11727 | 0.080 |
Why?
|
| Humans | 26 | 2021 | 744343 | 0.070 |
Why?
|
| Acute Disease | 1 | 2018 | 7149 | 0.070 |
Why?
|
| Incidence | 3 | 2020 | 20947 | 0.070 |
Why?
|
| Female | 16 | 2020 | 380194 | 0.070 |
Why?
|
| Arteries | 1 | 2011 | 1119 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2017 | 2149 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 4034 | 0.060 |
Why?
|
| Complement C4b | 1 | 2005 | 135 | 0.060 |
Why?
|
| Hypertension, Renovascular | 1 | 2005 | 123 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4386 | 0.060 |
Why?
|
| Time Factors | 5 | 2008 | 40075 | 0.060 |
Why?
|
| Cyclosporine | 2 | 2004 | 786 | 0.060 |
Why?
|
| Tissue Donors | 2 | 2005 | 2240 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 4479 | 0.060 |
Why?
|
| Risk Factors | 6 | 2020 | 72290 | 0.060 |
Why?
|
| Renal Artery Obstruction | 1 | 2005 | 248 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2005 | 1095 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2004 | 343 | 0.050 |
Why?
|
| Adult | 9 | 2018 | 214055 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 5686 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2018 | 684 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 3870 | 0.050 |
Why?
|
| Interferons | 1 | 2004 | 706 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11524 | 0.050 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2001 | 86 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 6756 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2006 | 4776 | 0.040 |
Why?
|
| Age Factors | 4 | 2011 | 18370 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2020 | 77449 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2005 | 9146 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 63114 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2017 | 23338 | 0.040 |
Why?
|
| Thrombosis | 1 | 2012 | 2968 | 0.040 |
Why?
|
| Tunica Media | 2 | 2008 | 113 | 0.040 |
Why?
|
| New England | 1 | 2020 | 1022 | 0.040 |
Why?
|
| Vitamin D | 1 | 2011 | 3223 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2004 | 1379 | 0.040 |
Why?
|
| Aged | 8 | 2017 | 163280 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4751 | 0.040 |
Why?
|
| Child | 2 | 2020 | 77709 | 0.040 |
Why?
|
| Adolescent | 2 | 2020 | 85781 | 0.040 |
Why?
|
| Tunica Intima | 2 | 2008 | 464 | 0.030 |
Why?
|
| Inflammation | 2 | 2012 | 10638 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2009 | 5317 | 0.030 |
Why?
|
| Immunosuppressive Agents | 2 | 2004 | 4149 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2008 | 6077 | 0.030 |
Why?
|
| Stents | 1 | 2005 | 3280 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 25043 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2005 | 5097 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 1462 | 0.030 |
Why?
|
| Cause of Death | 1 | 2003 | 3584 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1880 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2005 | 1972 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2018 | 40561 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 57776 | 0.030 |
Why?
|
| Compliance | 1 | 2011 | 104 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2008 | 3445 | 0.030 |
Why?
|
| Prognosis | 3 | 2018 | 29063 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 6487 | 0.020 |
Why?
|
| Georgia | 1 | 2011 | 186 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2018 | 2453 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2017 | 2225 | 0.020 |
Why?
|
| Health Surveys | 1 | 2020 | 4037 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 12245 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2012 | 676 | 0.020 |
Why?
|
| Mississippi | 1 | 2008 | 88 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2017 | 6365 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 1423 | 0.020 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 3778 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2020 | 53288 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2006 | 517 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 370 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 3176 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 8340 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 1200 | 0.020 |
Why?
|
| Health Personnel | 1 | 2018 | 3218 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2006 | 492 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 10252 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2006 | 915 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2006 | 608 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 12788 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 39050 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 35421 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 793 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2006 | 612 | 0.010 |
Why?
|
| Hematuria | 1 | 2005 | 235 | 0.010 |
Why?
|
| Prednisolone | 1 | 2004 | 334 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2008 | 2297 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 5442 | 0.010 |
Why?
|
| Kidney | 1 | 2018 | 7186 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2008 | 2971 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3200 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2008 | 15165 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2011 | 1161 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 41006 | 0.010 |
Why?
|
| Proteinuria | 1 | 2005 | 658 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7279 | 0.010 |
Why?
|
| Homocysteine | 1 | 2004 | 647 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 4420 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5952 | 0.010 |
Why?
|
| Models, Animal | 1 | 2006 | 2171 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 1836 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2004 | 1842 | 0.010 |
Why?
|
| Angiography | 1 | 2005 | 1639 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 2356 | 0.010 |
Why?
|
| Cholesterol | 1 | 2008 | 2917 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 1738 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 766 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 1838 | 0.010 |
Why?
|
| Calcium | 1 | 2011 | 5756 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2006 | 2258 | 0.010 |
Why?
|
| Nephrotic Syndrome | 1 | 2001 | 389 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2008 | 9849 | 0.010 |
Why?
|
| Risk | 1 | 2008 | 9687 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 15076 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 21746 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 19905 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2001 | 2957 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2004 | 8554 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 8480 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 13284 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 11725 | 0.000 |
Why?
|
| United States | 1 | 2011 | 69872 | 0.000 |
Why?
|
| Animals | 1 | 2006 | 168757 | 0.000 |
Why?
|